Company intelligence / Profile preview

Cirsium Biosciences

San Diego, California, United States

Ownership: Private
Development stage: Other

Overview

Cirsium Biosciences has developed a highly scalable, rapid, plant-based platform for producing recombinant adeno-associated viral (AAV) vectors, achieving up to an 80% reduction in manufacturing lead times for gene therapies; no clinical results yet as the company is focused on manufacturing technology, not specific therapeutic assets.

Modalities: Gene therapyAdeno-associated viral vectorBiologic
Industry: Non-Drug Biotech

Beyond the preview

Go deeper on Cirsium Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cirsium Biosciences.

Explore the full profile